StreetInsider.com News Articles

Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference

Wed, 02 Sep 2026 08:00:00 -0400

CARLSBAD, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m. ET in New York.

A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com.The webcast will be archived for at least 30 days following each presentation.

About

Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference

Wed, 02 Sep 2026 08:00:00 -0400

CARLSBAD, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m. ET in New York.

A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com.The webcast will be archived for at least 30 days following each presentation.

About

Form SCHEDULE 13G/A Design Therapeutics, Filed by: Point72 Asset Management, L.P.

Fri, 14 Aug 2026 16:13:00 -0400
si-local-file:///var/storage/secattach/20260814/26930453.html

Form SCHEDULE 13G/A Design Therapeutics, Filed by: Point72 Asset Management, L.P.

Fri, 14 Aug 2026 16:13:00 -0400
si-local-file:///var/storage/secattach/20260814/26930453.html

Form SCHEDULE 13G Design Therapeutics, Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:33:00 -0400
si-local-file:///var/storage/secattach/20260814/26925191.html

Form SCHEDULE 13G Design Therapeutics, Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:33:00 -0400
si-local-file:///var/storage/secattach/20260814/26925191.html

Design Therapeutics, Inc. (DSGN) Tops Q2 EPS by 3c

Mon, 03 Aug 2026 16:08:36 -0400

Design Therapeutics, Inc. (NASDAQ: DSGN) reported Q2 EPS of ($0.32), $0.03 better than the analyst estimate of ($0.35).
For earnings history and earnings-related data on Design Therapeutics, Inc. (DSGN) click here.

Form 10-Q Design Therapeutics, For: Jun 30

Mon, 03 Aug 2026 08:08:00 -0400
si-local-file:///var/storage/secattach/20260803/26854272.html

Form 10-Q Design Therapeutics, For: Jun 30

Mon, 03 Aug 2026 08:08:00 -0400
si-local-file:///var/storage/secattach/20260803/26854272.html

Design Therapeutics modifies Friedreich ataxia trial, posts Q2 2026 loss

Mon, 03 Aug 2026 08:04:03 -0400

Design Therapeutics, Inc. (Nasdaq: DSGN) reported a net loss of $20.2 million for the second quarter ended June 30, 2026, and announced modifications to its RESTORE-FA clinical trial for Friedreich ataxia, according to a company press release.
The company is adjusting ongoing cohorts in the RESTORE-FA trial based on four-week data reported in May 2026, which showed dose-dependent increases in endogenous frataxin mRNA and protein levels following intravenous dosing of DT-216P2. Trial modifications include continuing evaluation of 1 milligram per kilogram as the planned go-forward dose, targeting enrollment of 10 patients in a 12-week cohort, designating endogenous blood FXN protein percent

Design Therapeutics modifies Friedreich ataxia trial, posts Q2 2026 loss

Mon, 03 Aug 2026 08:04:03 -0400

Design Therapeutics, Inc. (Nasdaq: DSGN) reported a net loss of $20.2 million for the second quarter ended June 30, 2026, and announced modifications to its RESTORE-FA clinical trial for Friedreich ataxia, according to a company press release.
The company is adjusting ongoing cohorts in the RESTORE-FA trial based on four-week data reported in May 2026, which showed dose-dependent increases in endogenous frataxin mRNA and protein levels following intravenous dosing of DT-216P2. Trial modifications include continuing evaluation of 1 milligram per kilogram as the planned go-forward dose, targeting enrollment of 10 patients in a 12-week cohort, designating endogenous blood FXN protein percent

Form 8-K Design Therapeutics, For: Aug 03

Mon, 03 Aug 2026 08:04:00 -0400
si-local-file:///var/storage/secattach/20260803/26854245.html

Form 8-K Design Therapeutics, For: Aug 03

Mon, 03 Aug 2026 08:04:00 -0400
si-local-file:///var/storage/secattach/20260803/26854245.html

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

Mon, 03 Aug 2026 08:00:00 -0400

RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027

Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1

Cash and securities of $207.4 million at quarter-end provide strong financial runway

CARLSBAD, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported second quarter 2026 financial results and highlighted business updates and upcoming milestones across

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

Mon, 03 Aug 2026 08:00:00 -0400

RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027

Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1

Cash and securities of $207.4 million at quarter-end provide strong financial runway

CARLSBAD, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported second quarter 2026 financial results and highlighted business updates and upcoming milestones across

Design Therapeutics (DSGN) Reiterated at Overweight by Cantor Fitzgerald

Wed, 01 Jul 2026 06:59:45 -0400

Cantor Fitzgerald analyst Yanni Souroutzidis reiterated an Overweight rating on Design Therapeutics Inc (NASDAQ: DSGN).
The analyst commented, "USS is the more stable endpoint, and we now place more limited weight on frataxin given that approval will ultimately hinge on function. USS is the more stable endpoint, and the signal here looks real: against the EPI study’s placebo benchmark, the 1mpk USS result sits far out in the tail (~0.1% of random 4-patient draws) and the dose response is clean and consistent across cohorts. Rummey’s placebo-response work shows mFARS can be inflated by frequent testing and older baselines – and RESTORE-FA’s

Design Therapeutics begins patient dosing in Phase 1 DT-818 trial

Tue, 30 Jun 2026 08:00:48 -0400

Design Therapeutics, Inc. (Nasdaq: DSGN) announced the initiation of patient dosing in a Phase 1 multiple ascending dose (MAD) clinical trial evaluating DT-818 in adults with myotonic dystrophy type-1 (DM1), according to a company press release.

DT-818 is a GeneTAC small molecule designed to selectively reduce transcription of the mutant DMPK allele, which the company says addresses the underlying genetic cause of DM1. The disease is a progressive neuromuscular condition affecting skeletal muscle, heart, brain and other organs, estimated to affect more than 70,000 people in the United States.

The Phase 1 trial is an open-label study designed to evaluate the safety,

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

Tue, 30 Jun 2026 08:00:00 -0400

GeneTAC^® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1

CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the initiation of patient dosing in its Phase 1 multiple-ascending dose (MAD) clinical trial evaluating DT-818 in adults with myotonic dystrophy type-1 (DM1). DT-818 is a GeneTAC^® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1.

"Initiation of patient

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

Tue, 30 Jun 2026 08:00:00 -0400

GeneTAC^® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1

CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the initiation of patient dosing in its Phase 1 multiple-ascending dose (MAD) clinical trial evaluating DT-818 in adults with myotonic dystrophy type-1 (DM1). DT-818 is a GeneTAC^® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1.

"Initiation of patient

Form 4 Design Therapeutics, For: Jun 09 Filed by: George Simeon

Thu, 11 Jun 2026 16:41:00 -0400
si-local-file:///var/storage/secattach/20260611/26636415.html

Form 4 Design Therapeutics, For: Jun 09 Filed by: George Simeon

Thu, 11 Jun 2026 16:41:00 -0400
si-local-file:///var/storage/secattach/20260611/26636415.html

Form 4 Design Therapeutics, For: Jun 09 Filed by: LAPPE RODNEY W

Thu, 11 Jun 2026 16:16:00 -0400
si-local-file:///var/storage/secattach/20260611/26635871.html

Form 4 Design Therapeutics, For: Jun 09 Filed by: LAPPE RODNEY W

Thu, 11 Jun 2026 16:16:00 -0400
si-local-file:///var/storage/secattach/20260611/26635871.html

Form 4 Design Therapeutics, For: Jun 09 Filed by: Shapiro David

Thu, 11 Jun 2026 16:16:00 -0400
si-local-file:///var/storage/secattach/20260611/26635876.html

Form 4 Design Therapeutics, For: Jun 09 Filed by: Shapiro David

Thu, 11 Jun 2026 16:16:00 -0400
si-local-file:///var/storage/secattach/20260611/26635876.html